Kite Pharma, Inc. 4
4 · Kite Pharma, Inc. · Filed Mar 2, 2017
Insider Transaction Report
Form 4
Wiezorek Jeffrey
VP Clinical Development
Transactions
- Exercise/Conversion
Common Stock
2017-03-01$6.89/sh+18,000$124,020→ 39,071 total - Sale
Common Stock
2017-03-01$71.24/sh−259$18,451→ 38,738 total - Sale
Common Stock
2017-03-01$72.36/sh−328$23,734→ 38,410 total - Sale
Common Stock
2017-03-01$75.00/sh−16,561$1,242,075→ 21,849 total - Sale
Common Stock
2017-03-01$79.83/sh−160$12,773→ 21,071 total - Sale
Common Stock
2017-03-01$68.92/sh−74$5,100→ 38,997 total - Sale
Common Stock
2017-03-01$76.98/sh−150$11,547→ 21,542 total - Exercise/Conversion
Employee Stock Option (Right to Buy)
2017-03-01−18,000→ 68,000 totalExercise: $6.89Exp: 2024-06-05→ Common Stock (18,000 underlying) - Sale
Common Stock
2017-03-01$78.97/sh−311$24,560→ 21,231 total - Sale
Common Stock
2017-03-01$75.82/sh−157$11,904→ 21,692 total
Footnotes (11)
- [F1]Includes 376 shares acquired under the 2014 Employee Stock Purchase Plan on February 17, 2017.
- [F10]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $79.80 to $79.86, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
- [F11]On June 6, 2014, the Reporting Person was granted options to purchase an aggregate of 200,000 shares of the Issuer's common stock. 25,000 of such shares vested on November 30, 2015. The remaining 175,000 shares vest as follows: 25% on May 5, 2015, with the remaining shares vesting in 36 equal monthly installments thereafter.
- [F2]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 31, 2016.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $68.53 to $69.31, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
- [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.58 to $71.51, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
- [F5]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $71.91 to $72.79, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
- [F6]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $74.42 to $75.07, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
- [F7]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.56 to $76.15, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
- [F8]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $76.96 to $77.01, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
- [F9]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.58 to $79.41, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.